Litcius/Paper detail

Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis

Rahul S. Dalal, Emma McClure, Jenna Marcus, Jessica R. Allegretti

2022Digestive Diseases and Sciences16 citationsDOI

Topics & Concepts

VedolizumabMedicineInfliximabAdalimumabDiscontinuationInternal medicineUlcerative colitisHazard ratioGastroenterologyProportional hazards modelAdverse effectConfidence intervalRheumatoid arthritisDiseaseInflammatory Bowel DiseaseMicroscopic ColitisGastrointestinal motility and disorders
Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis | Litcius